Kos Pharmaceuticals News

What's eye-catching here is not the price of the deal, but the identity of the chief executive: Brian A. Markison, who was chief executive of King Pharmaceuticals, the specialty drug firm that was sold to Pfizer for $3.6 billion in 2010.

"As we position the company for our next phase of growth that includes manufacturing clinical materials for our inflammatory bowel disease program and initiating our Phase I clinical trial in IBD later this year, Christopher's broad experience in building young biotech companies, his strong insight into product development and his financial ... (more)

Abbott Laboratories' acquisition of Kos Pharmaceuticals, seems to have been driven by the double-digit growth of the market for lipid management products, a $20-billion segment, in which Kos Pharmaceuticals, has two prominent drugs that help raise the levels of "good cholesterol." On Monday, 6 November, 2006, the two companies had announced ... (more)